CN103977410A - 以聚缩酮为基质的蛋白类药物长效制剂的制备方法 - Google Patents
以聚缩酮为基质的蛋白类药物长效制剂的制备方法 Download PDFInfo
- Publication number
- CN103977410A CN103977410A CN201410147055.5A CN201410147055A CN103977410A CN 103977410 A CN103977410 A CN 103977410A CN 201410147055 A CN201410147055 A CN 201410147055A CN 103977410 A CN103977410 A CN 103977410A
- Authority
- CN
- China
- Prior art keywords
- preparation
- polyketals
- protein
- durative action
- taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 229920001855 polyketal Polymers 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 239000011159 matrix material Substances 0.000 title abstract 4
- 239000000463 material Substances 0.000 claims abstract description 13
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 8
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 8
- 239000004005 microsphere Substances 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 16
- 239000000839 emulsion Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 210000003022 colostrum Anatomy 0.000 claims description 14
- 235000021277 colostrum Nutrition 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 12
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 5
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 5
- 239000000854 Human Growth Hormone Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 229960004532 somatropin Drugs 0.000 claims description 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 4
- 229920000305 Nylon 6,10 Polymers 0.000 claims description 4
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 238000010612 desalination reaction Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- INKDAKMSOSCDGL-UHFFFAOYSA-N [O].OC1=CC=CC=C1 Chemical compound [O].OC1=CC=CC=C1 INKDAKMSOSCDGL-UHFFFAOYSA-N 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 5
- 239000007857 degradation product Substances 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract description 3
- 238000000465 moulding Methods 0.000 abstract description 2
- 239000003405 delayed action preparation Substances 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 238000009512 pharmaceutical packaging Methods 0.000 abstract 1
- 230000004952 protein activity Effects 0.000 abstract 1
- 238000002189 fluorescence spectrum Methods 0.000 description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940040591 biotech drug Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410147055.5A CN103977410A (zh) | 2014-04-14 | 2014-04-14 | 以聚缩酮为基质的蛋白类药物长效制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410147055.5A CN103977410A (zh) | 2014-04-14 | 2014-04-14 | 以聚缩酮为基质的蛋白类药物长效制剂的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103977410A true CN103977410A (zh) | 2014-08-13 |
Family
ID=51269729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410147055.5A Pending CN103977410A (zh) | 2014-04-14 | 2014-04-14 | 以聚缩酮为基质的蛋白类药物长效制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103977410A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104740641A (zh) * | 2015-04-08 | 2015-07-01 | 烟台大学 | 一种糖敏感的缓控释微球组合物及其制备方法 |
CN104940995A (zh) * | 2015-06-29 | 2015-09-30 | 哈尔滨工业大学 | 一种以牛血清白蛋白为基元反相微乳液制备蛋白质水凝胶微球的方法 |
CN105106174A (zh) * | 2015-09-06 | 2015-12-02 | 烟台大学 | 一种核-壳双层微球及其制备方法 |
CN108938600A (zh) * | 2018-07-11 | 2018-12-07 | 南京锐利施生物技术有限公司 | 玻璃体内注射的对抗体药物双重保护的微球及其制备方法 |
CN111407895A (zh) * | 2020-04-03 | 2020-07-14 | 丽水学院 | 一种多功能型聚缩酮药物缓释微球以及制备方法 |
-
2014
- 2014-04-14 CN CN201410147055.5A patent/CN103977410A/zh active Pending
Non-Patent Citations (1)
Title |
---|
YONGJIAO YU ET AL.: ""Preparation of PLGA/PCADK microsphere of BSA"", 《2013年中国药物制剂大会/论文汇编》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104740641A (zh) * | 2015-04-08 | 2015-07-01 | 烟台大学 | 一种糖敏感的缓控释微球组合物及其制备方法 |
CN104740641B (zh) * | 2015-04-08 | 2019-02-01 | 烟台大学 | 一种糖敏感的缓控释微球组合物及其制备方法 |
CN104940995A (zh) * | 2015-06-29 | 2015-09-30 | 哈尔滨工业大学 | 一种以牛血清白蛋白为基元反相微乳液制备蛋白质水凝胶微球的方法 |
CN104940995B (zh) * | 2015-06-29 | 2017-04-12 | 哈尔滨工业大学 | 一种以牛血清白蛋白为基元反相微乳液制备蛋白质水凝胶微球的方法 |
CN105106174A (zh) * | 2015-09-06 | 2015-12-02 | 烟台大学 | 一种核-壳双层微球及其制备方法 |
CN105106174B (zh) * | 2015-09-06 | 2018-04-27 | 烟台大学 | 一种核-壳双层微球及其制备方法 |
CN108938600A (zh) * | 2018-07-11 | 2018-12-07 | 南京锐利施生物技术有限公司 | 玻璃体内注射的对抗体药物双重保护的微球及其制备方法 |
CN108938600B (zh) * | 2018-07-11 | 2021-10-08 | 南京锐利施生物技术有限公司 | 玻璃体内注射的对抗体药物双重保护的微球及其制备方法 |
CN111407895A (zh) * | 2020-04-03 | 2020-07-14 | 丽水学院 | 一种多功能型聚缩酮药物缓释微球以及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vlachopoulos et al. | Poly (lactic acid)-based microparticles for drug delivery applications: An overview of recent advances | |
Makadia et al. | Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier | |
Shahriar et al. | Electrospinning nanofibers for therapeutics delivery | |
Chen et al. | Self-assembly pH-sensitive chitosan/alginate coated polyelectrolyte complexes for oral delivery of insulin | |
Mansour et al. | Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects | |
Wang et al. | Insulin-loaded silk fibroin microneedles as sustained release system | |
CN103977410A (zh) | 以聚缩酮为基质的蛋白类药物长效制剂的制备方法 | |
Prajapati et al. | Current knowledge on biodegradable microspheres in drug delivery | |
McKenzie et al. | Hydrogel-based drug delivery systems for poorly water-soluble drugs | |
Reinhold et al. | Self‐healing microencapsulation of biomacromolecules without organic solvents | |
RU2014102900A (ru) | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений | |
Cerbu et al. | Fate of biodegradable engineered nanoparticles used in veterinary medicine as delivery systems from a one health perspective | |
Hsu et al. | Nanoparticle-hydrogel composite drug delivery system for potential ocular applications | |
CN111346047B (zh) | 一种热致水凝胶二甲双胍缓释制剂及其制备方法和应用 | |
Ryu et al. | Dry tablet formulation of PLGA nanoparticles with a preocular applicator for topical drug delivery to the eye | |
JP2023159157A (ja) | 薬物送達組成物 | |
Ahmed | approaches to develop PLGA based in situ gelling system with low initial burst. | |
CN109414401A (zh) | 用于胃肠外给药的生物可降解聚合物微球组合物 | |
Cui et al. | Poloxamer-based scaffolds for tissue engineering applications: a review | |
Carvalho et al. | Polymeric-based drug delivery systems for veterinary use: State of the art | |
Camargo et al. | Ivermectin-loaded microparticles for parenteral sustained release: in vitro characterization and effect of some formulation variables | |
Khan et al. | Recent advances in microbeads-based drug delivery system for achieving controlled drug release | |
Jusu et al. | PLGA-CS-PEG microparticles for controlled drug delivery in the treatment of triple negative breast cancer cells | |
ES2336380T3 (es) | Formulacion farmaceuticas que comprenden dextrano con un peso molecular de 1,0-100 kda y procedimiento para su preparacion. | |
Mohammed-Sadhakathullah et al. | Advances in functionalization of bioresorbable nanomembranes and nanoparticles for their use in biomedicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING RUILISHI BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20150810 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150810 Address after: 130000 Jilin University, 2699 Qianjin Street, Jilin, Changchun Applicant after: Li Youxin Applicant after: Nanjing keen Biotechnology Co., Ltd. Address before: 130000 Jilin University, 2699 Qianjin Street, Jilin, Changchun Applicant before: Li Youxin |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140813 |